Inhibition of PARP enzymes leads to a synthetic lethality effect, resulting in erroneous repair of DNA damage and ultimately causing the death of tumor cells (Figure 1).[18] Several PARPi have been approved for clinical use: Olaparib (1), Rucaparib (2), Niraparib (3), Talazoparib (4), Fluzoparib (5), and Pamiparib (6) (Figure 2).[19] Olaparib is the first approved small‐molecule PARP1 inhibitor. Here, PARP1 is linked to neoplasm.